We recruited seropositive AQP4-neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease patients with serum samples available within 30 days of an attack (‘attack’) and at least one another sample for comparison within 1 year (‘pre-attack’ and ‘post-attack’). This evidence concerns the gene MOG and neuromyelitis optica.